Saxenda Injection, Solution
NDC Package 0169-2800-15
Package Information
Saxenda (liraglutide) injection is sAXENDA is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:•Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity.•Adults with overweight in the presence of at least one weight-related comorbid condition.Limitations of Use•SAXENDA contains liraglutide. This formulation utilizes a injection, solution delivery system. Marketed by Novo Nordisk Pharmaceutical Industries, Lp, this product is identified by NDC 0169-2800 and is authorized under FDA application NDA206321.
Identification & Billing
- RxCUI: 1598268 - Saxenda 6 MG/ML in 3 mL Weight Management Pen Injector
- RxCUI: 1598268 - Weight Management 3 ML liraglutide 6 MG/ML Pen Injector [Saxenda]
- RxCUI: 1598268 - 3 ML Saxenda 6 MG/ML Weight Management Pen Injector
- RxCUI: 1598268 - Saxenda 18 MG per 3 ML Weight Management Pen Injector
- RxCUI: 1598268 - Weight Management Saxenda 6 MG/ML Pen Injector
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0169 - Novo Nordisk Pharmaceutical Industries, Lp
- 0169-2800 - Saxenda
- 0169-2800-15 - 5 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC
- 0169-2800 - Saxenda
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0169-2800). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0169-2800-15 identifies a specific commercial package of 5 syringe, plastic in 1 carton / 3 ml in 1 syringe, plastic of Saxenda, a human prescription drug labeled by Novo Nordisk Pharmaceutical Industries, Lp. This injection, solution is formulated for subcutaneous use and contains liraglutide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novo Nordisk Pharmaceutical Industries, Lp on December 31, 2014. The current certification is valid through December 31, 2027.
How is this Novo Nordisk Pharmaceutical Industries, Lp product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00169280015. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 15 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.